Jasper Therapeutics stock gains 1.39 percent on Nasdaq

Jasper Therapeutics stock (ISIN US4718712023) was trading at USD 0.57 on Nasdaq on September 24, 2026, up 1.39 percent at 10:53 a.m. ET. The clinical-stage biotechnology company had announced two senior appointments on September 15, including leadership for regulatory affairs and clinical development, according to Jasper Therapeutics.

Q2 loss narrows sharply

Jasper reported a Q2 2026 net loss of USD 2.8 million, compared with USD 26.7 million in Q2 2025, according to Stock Titan. The USD 23.9 million year-over-year improvement reflects a lower reported loss, although the company remains dependent on financing and development milestones rather than product revenue.

The latest market data put Jasper's market capitalization at USD 9,340,352 on September 24, 2026. The stock's 52-week range was USD 0.32 to USD 2.69, leaving the USD 0.57 price 78.8 percent below the yearly high.

September 30 vote adds a checkpoint

Jasper has called a special stockholder meeting for September 30, 2026, to vote on three capital-structure proposals, according to Stock Titan. That date is a concrete corporate checkpoint for holders because the proposals could affect the company's share structure.

At the H.C. Wainwright conference on September 16, management described a three-asset clinical pipeline and cited USD 132 million from a PIPE financing plus a USD 12 million out-license payment, as reported by Investing.com. The funding figures provide a more measurable backdrop for the pipeline than the appointment news alone.

Stock gains 1.39 percent

Jasper Therapeutics stock stood at USD 0.57 on Nasdaq on September 24, 2026 at 10:53 a.m. ET. The USD 0.32 to USD 2.69 52-week range shows that the daily gain came with the shares still positioned well below the year's high.

More news and analyses on Jasper Therapeutics stock